252 related articles for article (PubMed ID: 36860165)
1. Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy.
Lordo MR; Stiff AR; Oakes CC; Mundy-Bosse BL
J Leukoc Biol; 2023 May; 113(5):518-524. PubMed ID: 36860165
[TBL] [Abstract][Full Text] [Related]
2. Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?
Zdrenghea MT
Med Hypotheses; 2013 Aug; 81(2):311-5. PubMed ID: 23669372
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
4. [Epigenetic therapy for hematologic malignancies].
Kobayashi Y
Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
[TBL] [Abstract][Full Text] [Related]
5. Immunological effects of hypomethylating agents.
Lindblad KE; Goswami M; Hourigan CS; Oetjen KA
Expert Rev Hematol; 2017 Aug; 10(8):745-752. PubMed ID: 28644756
[TBL] [Abstract][Full Text] [Related]
6. The future of epigenetic therapy in solid tumours--lessons from the past.
Azad N; Zahnow CA; Rudin CM; Baylin SB
Nat Rev Clin Oncol; 2013 May; 10(5):256-66. PubMed ID: 23546521
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
8. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
9. [Histone deacetylase inhibitors in the treatment of hematological malignancies].
Lemal R; Ravinet A; Moluçon-Chabrot C; Bay JO; Guièze R
Bull Cancer; 2011 Aug; 98(8):867-78. PubMed ID: 21827981
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt JS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
[TBL] [Abstract][Full Text] [Related]
11. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].
Grabarska A; Dmoszyńska-Graniczka M; Nowosadzka E; Stepulak A
Postepy Hig Med Dosw (Online); 2013 Aug; 67():722-35. PubMed ID: 24018438
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y; Sun Y; Yue S; Wang Y; Lu F
Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
[TBL] [Abstract][Full Text] [Related]
13. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
Beumer JH; Tawbi H
Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
Markozashvili D; Ribrag V; Vassetzky YS
Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
[TBL] [Abstract][Full Text] [Related]
15. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.
Kumar A; Emdad L; Fisher PB; Das SK
Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A; Zhou H; Yang J; Li M; Niu T
Signal Transduct Target Ther; 2023 Feb; 8(1):71. PubMed ID: 36797244
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
18. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
19. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
20. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
